Coronavirus disease 2019 (COVID-19) is caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2). Increased risk of thrombotic events is seen in patients infected with SARS-CoV-2, which is higher in patients needing critical care. In this touchCARDIO interview, we speak with Dr David Berg (Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA) to discuss the risks of thrombotic complications of COVID-19 and the unmet needs for preventative measures.
The abstract entitled ‘COVID-PACT – Antithrombotic therapy in critically Ill COVID-19 patients’ was presented at the European Society of Cardiology (ESC) Congress 2022, 26 – 29 August 2022.
Questions:
- Could you give us a brief overview of the risks of thrombotic complications of COVID-19? (0:20)
- What are the unmet needs in the prevention of thrombotic events in patients with COVID-19? (1:27)
Disclosures: David Berg has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Danielle Crosby.
Filmed as a highlight of ESC 2022
Access more content on COVID-19 here and Thrombosis here
